GH Research PLC (GHRS) vs Cyclerion Therapeutics, Inc. (KRSA)

GH Research PLC and Cyclerion Therapeutics, Inc. are both Biotechnology companies. GH Research PLC and Cyclerion Therapeutics, Inc. are of similar size ($1.7B and $1.7B). Across the 10 metrics below, GH Research PLC leads on 6 and Cyclerion Therapeutics, Inc. on 4.

Valuation

Metric GHRS KRSA Biotechnology median
P/E n/m n/m 7.88
P/S n/m 9.08 11.47
P/B 4.41 3.70 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 8.41 10.73
Earnings yield (4.19%) (37.47%) (28.84%)
Free cash flow yield (3.27%) (24.02%) (23.03%)

Profitability

Metric GHRS KRSA Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (18.79%) (98.22%) (57.72%)
Return on assets (18.16%) (82.29%) (49.22%)
Return on invested capital 0.00% (115.40%) 0.00%

Growth

Metric GHRS KRSA Biotechnology median
Revenue growth (TTM) — 30.77% 5.64%
EPS growth (last fiscal year) (5.33%) 8.26% —
Revenue growth, 5-year CAGR — (14.38%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GHRS KRSA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 28.70 0.82 4.73
Net debt to EBITDA 4.65 0.65 0.96

Dividend

Metric GHRS KRSA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GHRS KRSA Biotechnology median
Market cap 1.68b 1.69b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack